EcoDrugPlus

Protein Kinase D3

Ensembl ID : ENSAMXG00000008600
Gene Symbol: PRKD3
1 Cross references
218 Possible Orthologues:

Protein Kinase, Dna-Activated, Catalytic Subunit

Ensembl ID : ENSAMXG00000007058
Gene Symbol: PRKDC
1 Cross references
187 Possible Orthologues:

Protein Phosphatase 3 Catalytic Subunit Alpha

Ensembl ID : ENSAMXG00000042068
Gene Symbol: PPP3CA
4 Cross references
233 Possible Orthologues:

Protein Tyrosine Kinase 2

Ensembl ID : ENSAMXG00000004491
Gene Symbol: PTK2
1 Cross references
243 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta

Ensembl ID : ENSAMXG00000000798
Gene Symbol: PTK2B
3 Cross references
142 Possible Orthologues:

Protein Tyrosine Kinase 2 Beta, B

Ensembl ID : ENSAMXG00000019303
Gene Symbol: PTK2BB
1 Cross references
196 Possible Orthologues:

Protein Tyrosine Kinase 6

Ensembl ID : ENSAMXG00000038820
Gene Symbol: PTK6
1 Cross references
109 Possible Orthologues:

Protein Tyrosine Phosphatase Non-Receptor Type 11

Ensembl ID : ENSAMXG00000032054
Gene Symbol: PTPN11
3 Cross references
253 Possible Orthologues:

Protein Tyrosine Phosphatase Receptor Type B

Ensembl ID : ENSAMXG00000013469
Gene Symbol: PTPRB
1 Cross references
201 Possible Orthologues:

Proto-Oncogene Tyrosine-Protein Kinase Src

Ensembl ID : ENSAMXG00000001275
Gene Symbol: LOC103038924
3 Cross references
198 Possible Orthologues:

Purinergic Receptor P2x 3

Ensembl ID : ENSAMXG00000009787
Gene Symbol: P2RX3
3 Cross references
200 Possible Orthologues:

Purinergic Receptor P2x, Ligand-Gated Ion Channel, 3a

Ensembl ID : ENSAMXG00000015028
Gene Symbol: P2RX3A
1 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).